Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-08-07
2007-08-07
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S194100, C424S196110, C424S199100, C424S201100, C424S204100, C424S225100, C424S185100, C424S189100, C424S192100, C424S193100, C424S228100, C424S186100, C530S402000, C530S403000, C530S324000, C530S323000, C530S826000, C514S002600, C514S012200
Reexamination Certificate
active
08823980
ABSTRACT:
Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). Also disclosed are immunogenic compositions comprising a pharmaceutically acceptable carrier and the fusion protein.
REFERENCES:
patent: 4341761 (1982-07-01), Ganfield et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427783 (1984-01-01), Newman et al.
patent: 4444887 (1984-04-01), Hoffmann
patent: 4466917 (1984-08-01), Nussenzweig et al.
patent: 4472500 (1984-09-01), Milstein et al.
patent: 4491632 (1985-01-01), Wands et al.
patent: 4493890 (1985-01-01), Morris
patent: 4517304 (1985-05-01), Stott et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5308750 (1994-05-01), Mehta et al.
patent: 5574132 (1996-11-01), Lacroix
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5766845 (1998-06-01), Weiner et al.
patent: 5942234 (1999-08-01), Ralsten et al.
patent: 6146633 (2000-11-01), Stevens
patent: 0 116 201 (1984-08-01), None
patent: 0 120 551 (1984-10-01), None
patent: 0 164 556 (1985-12-01), None
patent: 0 259 149 (1988-03-01), None
patent: 0 360 088 (1990-03-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 468 527 (1992-01-01), None
patent: 0 725 824 (1996-08-01), None
patent: 0 759 937 (1997-03-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 90/11089 (1990-10-01), None
patent: WO 90/14436 (1990-11-01), None
patent: WO 90/14837 (1990-12-01), None
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/04205 (1993-04-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 93/16126 (1993-08-01), None
patent: WO 93/18054 (1993-09-01), None
Fahey et al., Clin. Exp. Immunol., 88: 1-5, 1992.
Berzosky et al. , Chapter 8, from “Fundamental Immunology, Second Edition” ed. W.E. Paul, Raven Press, 1989, pp. 176 and 177.
Barrett, J.T.,Basic Immunology and its medical application, Second Edition, 1980, 14-17.
Botarelli, P. et al., “T-Lymphocyte Response to Hepatitis C Virus in Different Clinical Courses of Infection”,Gastroenterology, 1993, 104, 580-587.
Brennan, M. et al., “The foliclle cells are a major site of vitellogenin inDrosophila melanogaster”, Dev. Biol.,1982, 89, 225-236.
Broach, R., “Construction of High Copy Yeast Vectors Using 2-μm Circle Sequences,”Meth. Enz.,1983, 101, 307-325.
Cha et al., “At least five related, but distinct, hepatitis C viral genotypes exist,”Proc. Natl. Acad. Sci USA,1992, 89, 7144-7148.
Chakrabarti et al., “Vaccinia Virus Expression Vector: Coexpression of β-Galactosidase Provides Visual Screening of Recombinant Virus Plaques,”Mol. Cell Biol.,1985, 5(12), 3403-3409.
Chan et al., “Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants,”J. Gen. Virol.,1992, 73, 1131-1141.
Choo et al., “Vaccination of chimpanzees against infection by the hepatitis C virus”,Proc. Natl. Acad. Sci. USA,1994, 91, 1294-1298.
Choo, Q.L. et al., “Genetic organization and diversity of the hepatitis C virus”,Proc. Natl. Acad. Sci. USA,1991, 88, 2451-2455.
Choo, Q.L. et al., “Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis”,Br. Med. Bull.,1990, 46(2), 423-441.
Choo, Q.L. et al., “Hepatitis C virus is a distant relative of the flaviviruses and pestiviruses”, inProceedings of the International Meeting on Non-A, Non-B Hepatitis,Shikata, T. et al. (eds.), Tokyo, Japan, Amsterdam: Elsevier, 1991, 47-52.
Choo, Q.L. et al., “Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome”,Science, 1989, 244, 359-362.
Choo, Q.L. et al., “Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach”,Seminars in Liver Disease,1992, 12(3), 279-288.
Cofin et al. (eds.),RNA Tumor Viruses,2nd Edition, Cold Spring Harbor Laboratory, New York, 1985, vol. 2, 17-73.
Cuypers, H.T. et al., “Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus”,J. Clin. Microbiol.,1992, 30(12), 3220-3224.
Cuypers, H.T.M. et al., “Analysis of genomic variability of hepatitis-C virus”,J. Hepatology,1991, 13(Suppl. 4), S15-S19.
DeBoer et al., “The tac promotor: a functional hybrid derived from the trp and lac promoters,”Proc. Natl. Acad. Sci. USA,1983, 80(1), 21-25.
Erickson, A.L. et al., “Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C”,J. Immunol.,1993, 151(8), 4189-4199.
Fausto-Sterling, A. et al., “Analysis of a newly-isolated temperature-sensitive maternal-effect mutation ofDrosophila melanogaster”, J. Exper. Zoo.,1976, 200, 199-209.
Fiers et al., “Complete nucleotide sequence of SV40 DNA,”Nature,1978, 273, 113-120.
Goeddel et al., “Synthesis of human fibroblast interferon byE. coli,” Nucl. Acids Res.,1980, 8(18), 4057-4075.
Guntaka, R.V. et al., “Effect of 5-Methyllcytidine on virus production in avian sarcoma virus-infected chicken embryo cells”,Virology,1979, 29(2), 475-482.
Guntaka, R.V. et al., “Effect of dibutyrlcyclic AMP on intracellular levels of avian sarcoma virus specific RNA”,Nature,1978, 274, 274-276.
Hess et al., “Cooperation of glycolytic enzymes,”J. Adv. Enzyme Reg.,1968, 7, 149-167.
Hitzeman et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique,”J. Biol. Chem.,1980, 255(24), 12073-12080.
Holland et al., “The primary structures of two yeast enolase genes,”J. Biol. Chem.,1981, 256(3), 1385-1395.
Holland et al., “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase,”Biochem.,1978, 17(23), 4900-4907.
Houghton, M. et al., “The hepatitis C virus: Genetic organization, persistence, and vaccine strategies,”Viral Hepatitis and Liver Disease,Nishioka, K. et al. (eds.), Springer-Verlag, Tokyo, 1994, 33-37.
Houghton, M. et al., “Hepatitis C virus: Structure, protein products and processing of the polyprotein precursor”,Curr. Stud. Hematol. Blood Transfus.(Switzerlaned), 1994, 61, 1-11.
Houghton, M. et al., “Hepatitis delta (δ) virus (HDV): Its relationship with introns and plant viroid-like agents and the mapping of immunogenic epitopes within viral polypeptides”,J. Med. Virol.,1987, 21(4), 37A, Abstract 106.
Houghton et al., “Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease, ”Hepatology,1991, 14(2), 381-388.
Jansen et al, “Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity,”Immun. Rev., 1982, 62, 185-216.
Jones et al., “The use of maleimidocaproyloxysuccinimide to prepare malarial peptide carrier immunogens,”J. Immunol. Methods,1989, 123, 211-216.
Kato et al., “Distribution of plural HCV types in Japan,”Biochem. Biophys. Res. Commun.,1991, 181(1), 279-285.
Kubo, Y. et al., “A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion, non-A, non-B hepatitis in Japan”,Nucl. Acids Res., 1989, 17(24), 10367-10372.
Lee et al., “A method for preparing β-hCG cooh peptide-carrier conjugate
Houghton Michael
Weiner Amy J.
Harbin Alisa A.
Lillis Marcella
Novartis Vaccines and Diagnostics Inc.
Robins Roberta L.
Schwadron Ronald B.
LandOfFree
Conserved motif of hepatitis C virus E2/NS1 region does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conserved motif of hepatitis C virus E2/NS1 region, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conserved motif of hepatitis C virus E2/NS1 region will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850446